Methotrexate-related minor adverse effects in rheumatoid arthritis: More than a nuisance

Journal of Clinical Rheumatology

Volumn 18, Issue 1, 2012, Pages 44-46

  Dhir, Varun ^a   Aggarwal, Amita ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ANOREXIA; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; SUPPLEMENTATION; TASTE DISORDER; VOMITING;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NAUSEA; QUESTIONNAIRES;

EID: 84855194910     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823ee540     Document Type: Article

References (20)

1. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086-1093.
2. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-328. (Pubitemid 24093622)
3. Weinblatt ME. Methotrexate in rheumatoid arthritis: Toxicity issues. Br J Rheumatol. 1996;35:403-405. (Pubitemid 26155695)
4. Gutierrez-Urena S, Molina JF, García CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:272-276. (Pubitemid 26065267)
5. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989;32:671-676. (Pubitemid 19179245)
6. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9-18. (Pubitemid 20040125)
7. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833-841.
8. Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD000951.
9. Hornung N, Ellingsen T, Stengaard-Pedersen K, et al. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol. 2004;31:2374-2381. (Pubitemid 39603084)
10. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095-3103. (Pubitemid 44622078)
11. Stamp LK, O'Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010;62:359-368.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324. (Pubitemid 18091653)
13. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515-1524. (Pubitemid 32651731)
14. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Invest. 2006;26:55-62. (Pubitemid 43275699)
15. Griffith SM, Fisher J, Clarke S, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatol. 2000;39:1102-1109.
16. Katchamart W, Bourré-Tessier J, Donka T, et al., Canadian 3E Initiative Consensus Group. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1422-1430.
17. Mainman H, McClaren E, Heycock C, et al. When should we use parenteral methotrexate? Clin Rheumatol. 2010;29:1093-1098.
18. Braun J, Kästner P, Flaxenberg P, et al. MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73-81.
19. Devlin J, Wagstaff K, Arthur V, et al. Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil). Rheumatol. 1999;38:280-282. (Pubitemid 29507165)
20. Kremer JM. Methotrexate treatment of rheumatic diseases: Can we do better? Arthritis Rheum. 2008;58:3279-3282.